Featured News

The Cribsiders Podcast on pediatric medicine recently released an episode with a special guest, Dr. Dale Lee from Seattle Children's Hospital, about the diagnosis and management of celiac disease.

Want to get involved in celiac disease research? It’s time to take action. The TEV-CeD Study is a phase 1b clinical trial testing the investigational medication TEV-53408 for the treatment of celiac disease.  

New research indicates that a specific set of natural memory T cells, when triggered by gluten, rapidly become destructive and cause intestinal damage in celiac disease patients.

As we look toward the summer months, the team here at the Celiac Disease Foundation is actively working on a number of new projects that are vital to elevating our mission to promote diagnosis, treatments, and a cure for celiac disease.

Congratulations to Celiac Disease Foundation research partner Takeda Pharmaceuticals and its Medical Director Dan Leffler on recent media attention for three potential celiac disease therapies.

This year, we are proud to acknowledge the outpouring of support we received during the month of May.  

During the month of May, the Celiac Disease Foundation is taking the opportunity to honor the advocacy efforts of our dedicated, inspiring celiac disease patient community.

The ILLUMINATE Studies are phase 2 clinical research studies evaluating an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.

Piecemeal solutions are no longer an option. It is time for a complete transformation of the health care system to promote unbiased structures and processes to advance equitable access to quality health care for all.

Consider joining the CeDar Rose Study, a remote celiac disease study that will monitor individual gluten tolerance.